对皮罗尼病的营养药干预措施的证据分析:基于指南的批判性审查
Daniele Tienforti1, Malvina Hoxha2, Alfonso Boris Di Pasquale3
1Andrology Unit, Department of Clinical Medicine, Life, Health and Environmental Sciences, University of L'Aquila, 67100 Coppito, L'Aquila, Italy.
Sexual medicine reviews
|May 29, 2024
概括
皮罗尼病的营养药治疗方法
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 安德罗学与人类学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮罗尼病 (PD) 的管理带来了临床挑战.
- 非手术治疗,特别是具有抗氧化特性的营养药,是常见的,但有争议.
- 由于缺乏病因治疗方法,需要探索替代管理策略.
研究的目的:
- 批判性地分析和比较主要泌尿学协会关于皮罗尼病的营养药干预措施的指导方针.
- 审查随机对照试验 (RCT) 的证据,以告知这些准则.
- 为了确定PD管理中营养药建议的不一致性.
主要方法:
- 系统地搜索主要数据库 (PubMed,Scopus,Web of Science,Cochrane Library) 的RCT,评论和关于PD营养药的指南.
- 对美国泌尿病学协会 (AUA),加拿大泌尿病学协会 (CUA),欧洲泌尿病学协会 (EAU) 和国际性医学协会 (ISSM) 的建议进行比较分析.
主要成果:
- 对PD中营养药的证据不一致;整体有效性有限.
- 卡尼丁的乙烯基在一些研究中显示出潜力,但在指导方针中不推使用.
- 辅酶Q10和甲基氨基酸在不同社会之间有相互矛盾的建议.
- 由于撤回的研究证据,不建议使用欧米茄-3脂肪酸.
结论:
- 主要泌尿器学会关于皮罗尼病营养药的指导方针存在重大不一致.
- 尽管经验使用,营养药物干预PD的整体有效性仍然值得怀疑.
- 需要进一步的研究来澄清特定营养药在PD管理中的作用,如果有的话.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167